Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related 		KEGG GENES KEGG DRUG DrugBank Disease ID
1 African trypanosomiasis 💬
 [1] IFNG 💬 Emapalumab 💬 Emapalumab [3] 49, 65, 107 💬
2 African trypanosomiasis 💬
 [1] IFNG 💬 Fontolizumab 💬 Fontolizumab [1] 46 💬
3 Allograft rejection 💬
 [1] IFNG 💬 Emapalumab 💬 Emapalumab [3] 49, 65, 107 💬
4 Allograft rejection 💬
 [1] IFNG 💬 Fontolizumab 💬 Fontolizumab [1] 46 💬
5 Amoebiasis 💬
 [1] IFNG 💬 Emapalumab 💬 Emapalumab [3] 49, 65, 107 💬
6 Amoebiasis 💬
 [1] IFNG 💬 Fontolizumab 💬 Fontolizumab [1] 46 💬
7 Antigen processing and presentation 💬
 [1] IFNG 💬 Emapalumab 💬 Emapalumab [3] 49, 65, 107 💬
8 Antigen processing and presentation 💬
 [1] IFNG 💬 Fontolizumab 💬 Fontolizumab [1] 46 💬
9 Chagas disease 💬
 [1] IFNG 💬 Emapalumab 💬 Emapalumab [3] 49, 65, 107 💬
10 Chagas disease 💬
 [1] IFNG 💬 Fontolizumab 💬 Fontolizumab [1] 46 💬
11 Chagas disease 💬
 [2] IFNGR1, IFNGR2 💬 Interferon gamma-1b 💬 Interferon gamma-1b [7] 18, 65, 85, 228, 299, 301, 326 💬
12 Cytokine-cytokine receptor interaction 💬
 [1] IFNG 💬 Emapalumab 💬 Emapalumab [3] 49, 65, 107 💬
13 Cytokine-cytokine receptor interaction 💬
 [1] IFNG 💬 Fontolizumab 💬 Fontolizumab [1] 46 💬
14 Cytokine-cytokine receptor interaction 💬
 [2] IFNGR1, IFNGR2 💬 Interferon gamma-1b 💬 Interferon gamma-1b [7] 18, 65, 85, 228, 299, 301, 326 💬
15 Fluid shear stress and atherosclerosis 💬
 [1] IFNG 💬 Emapalumab 💬 Emapalumab [3] 49, 65, 107 💬
16 Fluid shear stress and atherosclerosis 💬
 [1] IFNG 💬 Fontolizumab 💬 Fontolizumab [1] 46 💬
17 Graft-versus-host disease 💬
 [1] IFNG 💬 Emapalumab 💬 Emapalumab [3] 49, 65, 107 💬
18 Graft-versus-host disease 💬
 [1] IFNG 💬 Fontolizumab 💬 Fontolizumab [1] 46 💬
19 Hepatitis C 💬
 [1] IFNG 💬 Emapalumab 💬 Emapalumab [3] 49, 65, 107 💬
20 Hepatitis C 💬
 [1] IFNG 💬 Fontolizumab 💬 Fontolizumab [1] 46 💬
21 Herpes simplex virus 1 infection 💬
 [1] IFNG 💬 Emapalumab 💬 Emapalumab [3] 49, 65, 107 💬
22 Herpes simplex virus 1 infection 💬
 [1] IFNG 💬 Fontolizumab 💬 Fontolizumab [1] 46 💬
23 Herpes simplex virus 1 infection 💬
 [2] IFNGR1, IFNGR2 💬 Interferon gamma-1b 💬 Interferon gamma-1b [7] 18, 65, 85, 228, 299, 301, 326 💬
24 HIF-1 signaling pathway 💬
 [1] IFNG 💬 Emapalumab 💬 Emapalumab [3] 49, 65, 107 💬
25 HIF-1 signaling pathway 💬
 [1] IFNG 💬 Fontolizumab 💬 Fontolizumab [1] 46 💬
26 HIF-1 signaling pathway 💬
 [2] IFNGR1, IFNGR2 💬 Interferon gamma-1b 💬 Interferon gamma-1b [7] 18, 65, 85, 228, 299, 301, 326 💬
27 IL-17 signaling pathway 💬
 [1] IFNG 💬 Emapalumab 💬 Emapalumab [3] 49, 65, 107 💬
28 IL-17 signaling pathway 💬
 [1] IFNG 💬 Fontolizumab 💬 Fontolizumab [1] 46 💬
29 Inflammatory bowel disease 💬
 [1] IFNG 💬 Emapalumab 💬 Emapalumab [3] 49, 65, 107 💬
30 Inflammatory bowel disease 💬
 [1] IFNG 💬 Fontolizumab 💬 Fontolizumab [1] 46 💬
31 Inflammatory bowel disease 💬
 [2] IFNGR1, IFNGR2 💬 Interferon gamma-1b 💬 Interferon gamma-1b [7] 18, 65, 85, 228, 299, 301, 326 💬
32 Influenza A 💬
 [1] IFNG 💬 Emapalumab 💬 Emapalumab [3] 49, 65, 107 💬
33 Influenza A 💬
 [1] IFNG 💬 Fontolizumab 💬 Fontolizumab [1] 46 💬
34 Influenza A 💬
 [2] IFNGR1, IFNGR2 💬 Interferon gamma-1b 💬 Interferon gamma-1b [7] 18, 65, 85, 228, 299, 301, 326 💬
35 JAK-STAT signaling pathway 💬
 [1] IFNG 💬 Emapalumab 💬 Emapalumab [3] 49, 65, 107 💬
36 JAK-STAT signaling pathway 💬
 [1] IFNG 💬 Fontolizumab 💬 Fontolizumab [1] 46 💬
37 JAK-STAT signaling pathway 💬
 [2] IFNGR1, IFNGR2 💬 Interferon gamma-1b 💬 Interferon gamma-1b [7] 18, 65, 85, 228, 299, 301, 326 💬
38 Kaposi sarcoma-associated herpesvirus infection 💬
 [1] IFNGR1 💬 Interferon gamma-1b 💬 Interferon gamma-1b [7] 18, 65, 85, 228, 299, 301, 326 💬
39 Leishmaniasis 💬
 [1] IFNG 💬 Emapalumab 💬 Emapalumab [3] 49, 65, 107 💬
40 Leishmaniasis 💬
 [1] IFNG 💬 Fontolizumab 💬 Fontolizumab [1] 46 💬
41 Leishmaniasis 💬
 [2] IFNGR1, IFNGR2 💬 Interferon gamma-1b 💬 Interferon gamma-1b [7] 18, 65, 85, 228, 299, 301, 326 💬
42 Malaria 💬
 [1] IFNG 💬 Emapalumab 💬 Emapalumab [3] 49, 65, 107 💬
43 Malaria 💬
 [1] IFNG 💬 Fontolizumab 💬 Fontolizumab [1] 46 💬
44 Natural killer cell mediated cytotoxicity 💬
 [1] IFNG 💬 Emapalumab 💬 Emapalumab [3] 49, 65, 107 💬
45 Natural killer cell mediated cytotoxicity 💬
 [1] IFNG 💬 Fontolizumab 💬 Fontolizumab [1] 46 💬
46 Natural killer cell mediated cytotoxicity 💬
 [2] IFNGR1, IFNGR2 💬 Interferon gamma-1b 💬 Interferon gamma-1b [7] 18, 65, 85, 228, 299, 301, 326 💬
47 Necroptosis 💬
 [1] IFNG 💬 Emapalumab 💬 Emapalumab [3] 49, 65, 107 💬
48 Necroptosis 💬
 [1] IFNG 💬 Fontolizumab 💬 Fontolizumab [1] 46 💬
49 Necroptosis 💬
 [2] IFNGR1, IFNGR2 💬 Interferon gamma-1b 💬 Interferon gamma-1b [7] 18, 65, 85, 228, 299, 301, 326 💬
50 Osteoclast differentiation 💬
 [1] IFNG 💬 Emapalumab 💬 Emapalumab [3] 49, 65, 107 💬
51 Osteoclast differentiation 💬
 [1] IFNG 💬 Fontolizumab 💬 Fontolizumab [1] 46 💬
52 Osteoclast differentiation 💬
 [2] IFNGR1, IFNGR2 💬 Interferon gamma-1b 💬 Interferon gamma-1b [7] 18, 65, 85, 228, 299, 301, 326 💬
53 Pathways in cancer 💬
 [1] IFNG 💬 Emapalumab 💬 Emapalumab [3] 49, 65, 107 💬
54 Pathways in cancer 💬
 [1] IFNG 💬 Fontolizumab 💬 Fontolizumab [1] 46 💬
55 Pathways in cancer 💬
 [2] IFNGR1, IFNGR2 💬 Interferon gamma-1b 💬 Interferon gamma-1b [7] 18, 65, 85, 228, 299, 301, 326 💬
56 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 [1] IFNG 💬 Emapalumab 💬 Emapalumab [3] 49, 65, 107 💬
57 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 [1] IFNG 💬 Fontolizumab 💬 Fontolizumab [1] 46 💬
58 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 [2] IFNGR1, IFNGR2 💬 Interferon gamma-1b 💬 Interferon gamma-1b [7] 18, 65, 85, 228, 299, 301, 326 💬
59 Proteasome 💬
 [1] IFNG 💬 Emapalumab 💬 Emapalumab [3] 49, 65, 107 💬
60 Proteasome 💬
 [1] IFNG 💬 Fontolizumab 💬 Fontolizumab [1] 46 💬
61 Rheumatoid arthritis 💬
 [1] IFNG 💬 Emapalumab 💬 Emapalumab [3] 49, 65, 107 💬
62 Rheumatoid arthritis 💬
 [1] IFNG 💬 Fontolizumab 💬 Fontolizumab [1] 46 💬
63 Systemic lupus erythematosus 💬
 [1] IFNG 💬 Emapalumab 💬 Emapalumab [3] 49, 65, 107 💬
64 Systemic lupus erythematosus 💬
 [1] IFNG 💬 Fontolizumab 💬 Fontolizumab [1] 46 💬
65 T cell receptor signaling pathway 💬
 [1] IFNG 💬 Emapalumab 💬 Emapalumab [3] 49, 65, 107 💬
66 T cell receptor signaling pathway 💬
 [1] IFNG 💬 Fontolizumab 💬 Fontolizumab [1] 46 💬
67 TGF-beta signaling pathway 💬
 [1] IFNG 💬 Emapalumab 💬 Emapalumab [3] 49, 65, 107 💬
68 TGF-beta signaling pathway 💬
 [1] IFNG 💬 Fontolizumab 💬 Fontolizumab [1] 46 💬
69 Th1 and Th2 cell differentiation 💬
 [1] IFNG 💬 Emapalumab 💬 Emapalumab [3] 49, 65, 107 💬
70 Th1 and Th2 cell differentiation 💬
 [1] IFNG 💬 Fontolizumab 💬 Fontolizumab [1] 46 💬
71 Th1 and Th2 cell differentiation 💬
 [2] IFNGR1, IFNGR2 💬 Interferon gamma-1b 💬 Interferon gamma-1b [7] 18, 65, 85, 228, 299, 301, 326 💬
72 Th17 cell differentiation 💬
 [1] IFNG 💬 Emapalumab 💬 Emapalumab [3] 49, 65, 107 💬
73 Th17 cell differentiation 💬
 [1] IFNG 💬 Fontolizumab 💬 Fontolizumab [1] 46 💬
74 Th17 cell differentiation 💬
 [2] IFNGR1, IFNGR2 💬 Interferon gamma-1b 💬 Interferon gamma-1b [7] 18, 65, 85, 228, 299, 301, 326 💬
75 Toxoplasmosis 💬
 [1] IFNG 💬 Emapalumab 💬 Emapalumab [3] 49, 65, 107 💬
76 Toxoplasmosis 💬
 [1] IFNG 💬 Fontolizumab 💬 Fontolizumab [1] 46 💬
77 Toxoplasmosis 💬
 [2] IFNGR1, IFNGR2 💬 Interferon gamma-1b 💬 Interferon gamma-1b [7] 18, 65, 85, 228, 299, 301, 326 💬
78 Tuberculosis 💬
 [1] IFNG 💬 Emapalumab 💬 Emapalumab [3] 49, 65, 107 💬
79 Tuberculosis 💬
 [1] IFNG 💬 Fontolizumab 💬 Fontolizumab [1] 46 💬
80 Tuberculosis 💬
 [2] IFNGR1, IFNGR2 💬 Interferon gamma-1b 💬 Interferon gamma-1b [7] 18, 65, 85, 228, 299, 301, 326 💬
81 Type I diabetes mellitus 💬
 [1] IFNG 💬 Emapalumab 💬 Emapalumab [3] 49, 65, 107 💬
82 Type I diabetes mellitus 💬
 [1] IFNG 💬 Fontolizumab 💬 Fontolizumab [1] 46 💬

Back to top